Xeris Biopharma (XERS) Stock
Specialty drug maker for stable hormone treatments. Here's the price, business snapshot, and what's worth knowing about Xeris Biopharma in November 2026.
Xeris BioPharma Holdings, Inc. (XERS) is a commercial-stage biotechnology company focused on developing ready-to-use hormone formulations and novel drug-delivery technologies. Its best-known offering is a room-temperature-stable glucagon product for severe hypoglycaemia, designed to simplify emergency treatment compared with traditional reconstitution therapies. With a market capitalisation of about $1.47bn, Xeris sits between early-stage biotechs and larger speciality pharmaceutical firms: it has commercial revenue but remains dependent on product uptake, pricing and reimbursement dynamics. Investors should watch sales growth, supply-chain execution, regulatory decisions and the company’s ability to expand indications or launch additional formulations. Typical biotech risks — clinical, regulatory, competition and financing — apply, and share prices can be volatile. This summary is educational and not personal advice; investors should assess their own suitability and consult a financial adviser before acting. Past performance is not indicative of future results.
Xeris Biopharma (XERS) Stock Forecast
Analyst price target, next 12 months
$7.95
-22.1% vs today's $10.20
Price range over the last 12 months
Close to its 12-month high
Analysts covering Xeris Biopharma have a consensus 12-month target of $7.95, below the current price of $10.20.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Xeris Biopharma's stock, believing it could rise to $7.95.
Financial Health
Xeris Biopharma is earning good profits and revenue, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Commercial traction watch
Sales growth and market penetration for its glucagon product will be key indicators, though revenues can fluctuate and depend on reimbursement.
Formulation innovation
Xeris’s ready-to-use formulations can simplify care and offer differentiation, but clinical and regulatory hurdles remain for new applications.
Market and competition
Competition from larger pharma and evolving treatment standards may affect pricing and uptake; market dynamics should be monitored closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
